Crescent Capital BDC (NASDAQ:CCAP) Price Target Lowered to $19.00 at Oppenheimer

by · The Cerbat Gem

Crescent Capital BDC (NASDAQ:CCAP – Get Free Report) had its target price lowered by Oppenheimer from $20.00 to $19.00 in a note issued to investors on Friday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Oppenheimer’s price objective would indicate a potential upside of 39.96% from the company’s previous close.

Other equities research analysts have also recently issued reports about the company. Zacks Research cut Crescent Capital BDC from a “hold” rating to a “strong sell” rating in a research note on Wednesday, October 15th. Keefe, Bruyette & Woods dropped their price objective on Crescent Capital BDC from $17.00 to $15.50 and set an “outperform” rating on the stock in a research note on Friday. Wells Fargo & Company decreased their target price on Crescent Capital BDC from $15.00 to $14.00 and set an “equal weight” rating for the company in a research note on Friday. Finally, LADENBURG THALM/SH SH upgraded Crescent Capital BDC to a “strong-buy” rating in a report on Friday, August 15th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $16.38.

Check Out Our Latest Stock Report on CCAP

Crescent Capital BDC Trading Down 0.1%

Shares of NASDAQ CCAP traded down $0.02 during mid-day trading on Friday, reaching $13.58. The company had a trading volume of 155,996 shares, compared to its average volume of 193,801. The company has a 50-day moving average price of $14.55 and a two-hundred day moving average price of $14.86. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.27 and a current ratio of 1.27. Crescent Capital BDC has a 1-year low of $13.30 and a 1-year high of $20.19.

Crescent Capital BDC (NASDAQ:CCAP – Get Free Report) last posted its quarterly earnings data on Wednesday, November 12th. The company reported $0.46 EPS for the quarter, missing analysts’ consensus estimates of $0.47 by ($0.01). Crescent Capital BDC had a return on equity of 9.71% and a net margin of 20.84%.The firm had revenue of $41.35 million during the quarter, compared to analyst estimates of $42.35 million. On average, research analysts expect that Crescent Capital BDC will post 2.09 EPS for the current fiscal year.

Insider Buying and Selling at Crescent Capital BDC

In other news, Director Raymond Barrios bought 3,245 shares of the company’s stock in a transaction that occurred on Monday, August 25th. The stock was bought at an average price of $15.63 per share, with a total value of $50,719.35. Following the acquisition, the director owned 19,177 shares of the company’s stock, valued at approximately $299,736.51. This represents a 20.37% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 1.14% of the company’s stock.

Hedge Funds Weigh In On Crescent Capital BDC

Several institutional investors have recently bought and sold shares of the stock. Kovitz Investment Group Partners LLC boosted its holdings in shares of Crescent Capital BDC by 14.4% during the 1st quarter. Kovitz Investment Group Partners LLC now owns 202,873 shares of the company’s stock valued at $3,473,000 after purchasing an additional 25,528 shares during the last quarter. Invesco Ltd. boosted its position in Crescent Capital BDC by 59.7% in the 1st quarter. Invesco Ltd. now owns 29,197 shares of the company’s stock valued at $500,000 after buying an additional 10,911 shares during the period. BI Asset Management Fondsmaeglerselskab A S increased its position in shares of Crescent Capital BDC by 39.5% during the first quarter. BI Asset Management Fondsmaeglerselskab A S now owns 63,893 shares of the company’s stock worth $1,094,000 after acquiring an additional 18,078 shares during the period. HighTower Advisors LLC lifted its holdings in Crescent Capital BDC by 0.5% during the first quarter. HighTower Advisors LLC now owns 137,366 shares of the company’s stock worth $2,352,000 after buying an additional 702 shares during the period. Finally, Mackenzie Financial Corp acquired a new position in Crescent Capital BDC in the 1st quarter worth approximately $804,000. 49.46% of the stock is owned by hedge funds and other institutional investors.

About Crescent Capital BDC

(Get Free Report)

Crescent Capital BDC, Inc is as a business development company private equity / buyouts and loan fund. It specializes in directly investing. It specializes in middle market. The fund seeks to invest in United States.

Further Reading